Cover Image
市場調查報告書

TiGenix NV的產品平台分析

TiGenix NV - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251727
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
TiGenix NV的產品平台分析 TiGenix NV - Product Pipeline Review - 2015
出版日期: 2015年09月23日 內容資訊: 英文 31 Pages
簡介

TiGenix NV是總公司設立於比利時的細胞治療藥開發企業,有障礙部分用植入式自體軟骨等醫療產品等臨床階段的平台產品。

本報告提供TiGenix NV的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

TiGenix NV的基本資料

  • TiGenix NV概要
  • 主要資訊
  • 企業資料

TiGenix NV:R&D概要

  • 主要的治療範圍

TiGenix NV:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

TiGenix NV:開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

TiGenix NV:藥物簡介

  • Cx-601
  • Cx-611
  • Cx-602
  • Cx-603
  • Cx-911

TiGenix NV:開發平台分析

  • 各給藥途徑
  • 各分子類型

TiGenix NV:最新的開發平台資訊

TiGenix NV:開發暫停中的計劃

TiGenix NV:開發中止的開發中產品

  • 開發中止的開發中產品簡介

TiGenix NV:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07604CDB

Summary

Global Markets Direct's, 'TiGenix NV - Product Pipeline Review - 2015', provides an overview of the TiGenix NV's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of TiGenix NV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of TiGenix NV including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of TiGenix NV's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the TiGenix NV's pipeline products

Reasons to buy

  • Evaluate TiGenix NV's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of TiGenix NV in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the TiGenix NV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of TiGenix NV and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of TiGenix NV
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of TiGenix NV and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • TiGenix NV Snapshot
    • TiGenix NV Overview
    • Key Information
    • Key Facts
  • TiGenix NV - Research and Development Overview
    • Key Therapeutic Areas
  • TiGenix NV - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • TiGenix NV - Pipeline Products Glance
    • TiGenix NV - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • TiGenix NV - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • TiGenix NV - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • TiGenix NV - Drug Profiles
    • Cx-601
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTX-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cx-611
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AlloCSC-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTX-201
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • TiGenix NV - Pipeline Analysis
    • TiGenix NV - Pipeline Products by Route of Administration
    • TiGenix NV - Pipeline Products by Molecule Type
  • TiGenix NV - Recent Pipeline Updates
  • TiGenix NV - Dormant Projects
  • TiGenix NV - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • TiGenix NV, Key Information
  • TiGenix NV, Key Facts
  • TiGenix NV - Pipeline by Indication, 2015
  • TiGenix NV - Pipeline by Stage of Development, 2015
  • TiGenix NV - Monotherapy Products in Pipeline, 2015
  • TiGenix NV - Phase III, 2015
  • TiGenix NV - Phase II, 2015
  • TiGenix NV - Phase I, 2015
  • TiGenix NV - Preclinical, 2015
  • TiGenix NV - Pipeline by Route of Administration, 2015
  • TiGenix NV - Pipeline by Molecule Type, 2015
  • TiGenix NV - Recent Pipeline Updates, 2015
  • TiGenix NV - Dormant Developmental Projects,2015
  • TiGenix NV, Subsidiaries

List of Figures

  • TiGenix NV - Pipeline by Top 10 Indication, 2015
  • TiGenix NV - Pipeline by Stage of Development, 2015
  • TiGenix NV - Monotherapy Products in Pipeline, 2015
  • TiGenix NV - Pipeline by Top 10 Route of Administration, 2015
  • TiGenix NV - Pipeline by Top 10 Molecule Type, 2015
Back to Top